Creating a new treatment for the viral skin disease Molluscum Contagiosum
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum
This study is working on a new treatment for Molluscum Contagiosum, a contagious skin condition that mainly affects kids, by creating a special medicine that targets the virus and aims to make treatment easier and less painful.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fox Chase Chemical Diversity Center, INC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project ID | NIH-10822148 on NIH RePORTER |
What this research studies
This research focuses on developing a peptide-drug conjugate specifically designed to treat Molluscum Contagiosum, a contagious skin disease caused by a virus. The approach involves identifying a viral protein target and creating a surrogate virus to test potential antiviral compounds. By synthesizing a small molecule that binds to this target, the research aims to provide a more effective and less painful treatment option for patients, particularly children who are most affected by this condition. The goal is to offer a solution that is both safe and effective, addressing the current unmet medical need.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who are diagnosed with Molluscum Contagiosum.
Not a fit: Patients with other skin conditions or those who are not affected by Molluscum Contagiosum may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective topical treatment for Molluscum Contagiosum, reducing the duration and discomfort of the disease.
How similar studies have performed: While there has been limited success with similar approaches due to the challenges in developing treatments for this virus, the innovative methods being employed in this research represent a novel attempt to address the issue.
Where this research is happening
Doylestown, United States
- Fox Chase Chemical Diversity Center, INC — Doylestown, United States (Active)
Researchers
- Principal investigator: Ricciardi, Robert Paul — Fox Chase Chemical Diversity Center, INC
- Study coordinator: Ricciardi, Robert Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.